NCT00470015View on ClinicalTrials.gov

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

January 2, 2013

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

MART-1 antigen

1000 mcg; Day 1 of a 21 day cycle x 4

BIOLOGICAL

IL-2

0.5x10\^6/m\^2

BIOLOGICAL

gp100 antigen

1000 mcg; Day 1 of a 21 day cycle x 4

BIOLOGICAL

GM-CSF

300mcg

BIOLOGICAL

MART-1a peptide

1000 mcg; Day 1 of a 21 day cycle x 4

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER